Compare NSP & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | NEO |
|---|---|---|
| Founded | 1986 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1996 | 2008 |
| Metric | NSP | NEO |
|---|---|---|
| Price | $36.84 | $11.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $47.67 | $13.38 |
| AVG Volume (30 Days) | 794.8K | ★ 2.4M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 6.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $6,812,000,000.00 | N/A |
| Revenue This Year | $3.45 | $10.63 |
| Revenue Next Year | $6.95 | $9.73 |
| P/E Ratio | $38.76 | ★ N/A |
| Revenue Growth | ★ 3.51 | N/A |
| 52 Week Low | $18.57 | $4.72 |
| 52 Week High | $63.30 | $13.74 |
| Indicator | NSP | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 65.42 |
| Support Level | $34.14 | $11.49 |
| Resistance Level | $38.30 | $11.62 |
| Average True Range (ATR) | 2.41 | 0.63 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 68.40 | 88.69 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.